Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 1,000 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 1,000 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $69.74, for a total value of $69,740.00. Following the completion of the transaction, the insider owned 37,793 shares in the company, valued at approximately $2,635,683.82. The trade was a 2.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Rahul Khara also recently made the following trade(s):

• On Friday, January 2nd, Rahul Khara sold 6,500 shares of Disc Medicine stock. The shares were sold at an average price of $78.69, for a total transaction of $511,485.00.

Disc Medicine Stock Up 1.2%

IRON stock traded up $0.89 during midday trading on Wednesday, reaching $74.89. 440,486 shares of the company were exchanged, compared to its average volume of 421,813. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. Disc Medicine, Inc. has a 1-year low of $30.82 and a 1-year high of $99.50. The stock’s 50-day simple moving average is $85.06 and its 200 day simple moving average is $72.95.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on IRON shares. Wedbush restated an “outperform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. National Bankshares set a $153.00 target price on Disc Medicine in a research report on Friday, October 17th. UBS Group reiterated an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Morgan Stanley restated an “overweight” rating and issued a $120.00 price target on shares of Disc Medicine in a report on Thursday, January 8th. Finally, TD Cowen restated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $119.45.

Institutional Trading of Disc Medicine

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Disc Medicine by 22.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after acquiring an additional 2,807 shares during the period. Millennium Management LLC boosted its position in Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after purchasing an additional 100,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Disc Medicine by 3.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock valued at $4,793,000 after buying an additional 3,454 shares during the period. Strs Ohio acquired a new position in shares of Disc Medicine during the first quarter worth $347,000. Finally, Avanza Fonder AB acquired a new stake in shares of Disc Medicine during the second quarter valued at about $57,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.